イスラエル - 英語 - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 4 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

イスラエル - 英語 - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 6 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

イスラエル - 英語 - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 8 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

イスラエル - 英語 - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium lauryl sulfate; crospovidone; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - ausgem is indicated as an adjunct to diet and other therapeutic measures for the following conditions: -severe hypertiglyceridamia (types iv and v) in those who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. -dyslipidaemia associated with diabetes. -reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. beacause of potential toxicity such as malignancy, gallbladder disease, abnormal pain leading to appendectomy and other abdominal surgeries, an increased incidence in non-coronary mortality and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevation of ldl-cholesterol only are not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above-median hdl-cholesterol values at baseline (>1.2mmol/l), both gemfibrozil and placebo subgroups had similar incidences of serious coronary events. note: ausgem is indicated when exercise, weight loss and specific dietary or other non-drug measures, for example, limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determinations of serum lipids should be obtained during treatment with ausgem. the drug should be withdrawn or additional therapy instituted if the lipid response is deemed inadequate after 3 months.

イスラエル - 英語 - Ministry of Health

abic marketing ltd, israel - lorcaserin hydrochloride hemihydrate - film coated tablets - lorcaserin hydrochloride hemihydrate 10.4 mg - lorcaserin - belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (bmi) of:• 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)

イスラエル - 英語 - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 10 mg - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

イスラエル - 英語 - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 12 mg - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

イスラエル - 英語 - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

イスラエル - 英語 - Ministry of Health

novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.